A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Mar 2019 Planned initiation date changed from 1 Mar 2019 to 26 Apr 2019.
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 15 Feb 2019 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.